have a three-dimensional lining made up of amino-acid side chains from helices 1, 2, 3, 6 and 7. These similarities indicate that the allosteric pocket might be present in other chemo kine receptors. If this supposition holds true, medicinal and computational chemists will have a field day using structure-aided design strategies to develop drugs that target the pocket. Vercirnon, for example, was not optimized for the CCR9 pocket, and it is likely that some minor alterations would improve its drug properties.
, and for a viral chemokine receptor in complex with the human chemokine CX3CL1 (ref. 7) , there is not yet a structure of a human chemokine receptor in complex with a human chemokine. Chemokines themselves are relatively complex protein ligands, generally comprising about 70 amino acids. What is clear is that multiple regions of the extracellular surface of chemokine receptors have roles in docking the chemo kine before it can engage the orthosteric pocket in the helix bundle 11 . Identification of a cytoplasmic allosteric binding pocket in chemokine receptors is especially valuable, because it provides an alternative strategy for structure-based drug discovery before the precise binding mode of chemokines has been fully elucidated.
Progress in developing useful small-molecule drugs for chemokine receptors has been slow. There have been just two successesmara viroc, which targets CCR5 to prevent HIV-1 from entering cells, and plerixafor, which targets CXCR4 to mobilize bonemarrow stem cells for transplantation in people with cancer. Another dozen or so chemo kine receptors are drug targets for diseases ranging from autoimmune disorders to cancer metastasis. The intracellular binding pocket identified in the current studies might provide a new strategy for inhibiting these receptors, by turning drugdiscovery efforts inside out. 1 report a strategy that allows ketoreductase enzymes to perform completely different reactions from the ones that they evolved to catalyse.
Living organisms are without doubt the best chemists on Earth -a plethora of reaction types is catalysed by the thousands of different enzymes present in every cell. The reactions take place with excellent selectivity (forming solely the desired product), astonishing efficiency (performing hundreds of catalytic reactions per second at a single catalytic site) and at ambient temperatures and pH values. By contrast, chemists have developed methods that allow a range of reactions with no enzymatic counterpart to be easily performed. In many cases, developing an enzyme that can perform such reactions is desirable.
Researchers have therefore devised a range of concepts for creating or modifying proteins to catalyse reactions unknown in nature [2] [3] [4] . One approach is to incorporate chemical transition-metal catalysts into protein scaffolds. As early as 1978, the protein avidin was modified to incorporate a rhodium catalyst 5 , producing an enzyme that catalyses asymmetric hydrogenationstransformations in which hydrogen reacts with organic molecules to produce products predominantly as one mirror-image isomer (enantiomer). This year, a system in which a ruthenium catalyst was incorporated into the streptavidin protein enabled olefin metathesis (a carbon-carbon bond-formation reaction; Fig. 1a ) in vivo in the bacterium Escherichia coli 6 . A second general approach is to use protein engineering to redesign enzymes to catalyse reactions other than the native one. This strategy is exemplified by the engineering of P450 monooxygenase enzymes 7 to catalyse carbon-carbon bond-formation reactions (cyclopropanations; Fig. 1b) , rather than the analogous carbon-oxygen bond-formation reactions (epoxidations) that occur naturally. A third approach is computational de novo protein design, which has been used to make an enzyme that catalyses the Kemp elimination reaction, in which a hydrogen ion (H + ) is removed from a carbon atom in an organic molecule (Fig. 1c) 
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. Subsequent extensive protein engineering through directed evolution of the enzyme resulted in catalytically efficient mutants 9 . Emmanuel et al. now report a striking new concept for generating enzymes that catalyse unnatural reactions: the authors use light to excite a cofactor (NAD(P)H) bound in the active site of a ketoreductase (KRED) enzyme. The resulting photoexcited cofactor generates a radical intermediate that serves as a hydrogen source. Furthermore, this hydrogen source is chiral -it has a 'handedness' that can potentially be passed on to other molecules during reactions. The authors find that, when KRED contains a photoexcited cofactor, it catalyses a reaction in which a halogen atom is removed from molecules known as halolactones, 22255-22259 (2010 and thus generating a radical intermediate that accepts a hydrogen atom to form the final product enantio selectively (see Fig. 3d of the paper 1 ). They nicely confirm this mechanism by generating a deuterium donor from NAD(P)H in situ in KRED, and observing where the deuterium is incorporated into the reaction products.
Emmanuel et al. have demonstrated a completely new strategy for accessing unnatural enzymatic reactions by exploring the interface between photochemistry and protein science. Other synthetic transformations can be envisaged with this approach, by using light-induced changes in NAD(P)H analogues or other cofactors. For instance, the well-studied flavin co factors (flavin adenine dinucleotide, flavin mononucleotide and their artificial analogues) could be prime candidates for investigation, because various flavin-dependent enzymes are important biological catalysts used by synthetic chemists 10 . In combination with modern tools for protein engineering 11 , the authors' concept is likely to have a strong impact on the use of various enzyme classes in biocatalysis. ■ forming products predominantly as one enantiomer (Fig. 1d) . Moreover, the enantiomer that is formed depends on the preference of the KRED that is used. The authors show that this unnatural reaction can be used to generate either of the enantiomers of products formed from a broad range of halolactones, demonstrating the synthetic usefulness of this approach.
Uwe T. Bornscheuer is in the Department
The KRED fulfils two functions in this reaction. First, it ensures productive, coordinated binding of the photoexcited NAD(P)H with the halolactone in its active site. But it also recycles the spent cofactor by reacting it with isopropanol (a component of the reaction mixture), regenerating NAD(P)H. This efficient recycling enables a KRED molecule to mediate multiple catalytic cycles, as would be needed for the enzyme to be used to make gram or kilogram quantities of product for industrial applications.
Not all the KREDs investigated by the authors could catalyse the reaction; Emmanuel and colleagues found that certain point mutations in the enzyme are needed to promote the productive binding of NAD(P)H within the enzyme's scaffold. However, the catalytically active KREDs bind the halolactones perfectly, even though they do not resemble the enzymes' natural substrates. Furthermore, the authors proved that the unnatural reaction occurs only when NAD(P)H is tightly bound to KRED and is irradiated with blue light.
The authors proposed a mechanism for the reaction in which light irradiation causes an electron to be transferred between the NAD(P)H and the substrate, triggering cleavage of the substrate's carbon-halogen bond, 1 now report that the cofactor NAD(P)H can be excited by blue light in ketoreductase (KRED) enzymes. This enables the enzyme to catalyse an unnatural reaction known as radical-induced dehalogenation, which yields the product as predominantly one mirror-image isomer (enantiomer). Et, ethyl; Cl, chlorine; Br, bromine.
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A gene-expression profile for leukaemia
Can simple genetic risk profiles be identified for complex diseases? The development of a gene-expression profile for acute myeloid leukaemia suggests that they can, and that they may improve prognosis prediction. See Letter p.433
G E R R I T J . S C H U U R H U I S
O n page 433, Ng et al. 1 report a tool that improves the prediction of prognoses for people who have a form of acute leukaemia. The researchers began by identifying populations of cells that exhibit key properties -collectively known as stemness -that enable the cells to initiate and sustain leukaemia. This allowed the authors to ascertain gene-expression profiles for stemness, and to use them as the basis of a scoring system for risk. The work demonstrates how gene-expression profiles can be used to enable reliable prognoses for complex diseases.
Acute myeloid leukaemia (AML) is characterized by the presence of a huge range of chromosomal and molecular aberrations. This means that there are many subgroups of people with AML who have widely different prognoses 2 . These groups are known as risk groups, and are used to determine which consolidation treatment should be given following initial chemotherapy (induction therapy). For example, transplantation of stem cells from donors is an option for patients judged to be
